Ivermectin, a silver bullet for infectious diseases caused by parasites that cause blindness, was not effective in reducing the risk of hospitalization even when administered to patients with the new coronavirus. The research group announced.
The results of the clinical trials were published in the international medical journal The New England Journal of Medicine by research groups such as universities in Brazil.
From March to August last year, the research group took 1358 ivermectin daily within 7 days of the onset of 1358 patients aged 18 years or older who were at risk of becoming more severe with new corona, such as obesity, diabetes, and hypertension. The course was examined by dividing into a group taking fake medicine and a group taking fake medicine for 3 days.
As a result, 14.7% of the patients who were hospitalized or visited the emergency outpatient department within 4 weeks were in the group taking ivermectin and 16.3% were in the fake drug group, showing no statistically significant difference. about it.
In addition, there was no difference in the period from the onset to the time when the viral load in the body decreased or recovered on the 7th day, and the risk of death.
"Ivermectin" is a silver bullet for diseases that cause blindness and swelling of lymphatic vessels by parasites, which was developed based on the research of Professor Satoshi Omura of Kitasato University, who won the Nobel Prize in Physiology or Medicine. Research has been conducted on its efficacy and safety for patients.
This clinical trial is conducted in a highly objective way that neither the patient nor the doctor who administers it can tell whether it is "ivermectin" or a fake drug. Even if it was administered, it did not show the effect of reducing the risk of hospitalization due to worsening of symptoms.